Chengbin Wu is the founder of EpimAb Biotherapeutics. EpimAb Biotherapeutics has raised $219M in total funding. Latest round: Series C. Based in China.
Chengbin Wu is the CEO of EpimAb Biotherapeutics, a clinical-stage biotech company based in China specializing in bispecific antibody development. He has led the company through multiple funding rounds and advanced programs such as EMB-07 and EMB-01 toward clinical approval.
Full founder directory · Investor directory · Company funding database · Fundraising library